12779
Dr.Deyn Natthakhet Yaemim, written on 28 Janruary 2019. Last reviewed 3 March 2021
. . .
Efforts to develop a hepatitis C vaccine started more than 25 years ago, when the hepatitis C virus was identified. Since then, researchers have studied more than 20 potential vaccines in animals. A few of these vaccines, developed mainly in the past decade, have undergone limited testing in people.
The following two clinical trials are now underway to find out if recently developed experimental vaccines are safe and effective in people.
The study population in this trial consists of people who already have chronic hepatitis C. The purpose of the trial is to determine whether each vaccine is safe and successful at reducing evidence of hepatitis C in participants' blood. Completion of this trial is expected in 2020.
This trial involves people at high risk of becoming infected with hepatitis C. Its purpose is to determine the safety of the two vaccines and find out whether participants receiving either vaccine are less likely to become infected with the hepatitis C virus over a six-month period than are participants receiving a placebo (inactive) vaccine. This trial has already enrolled a large sample of participants. It ends in July 2018.
If these trials have good results, larger trials will still be necessary to verify this effect and determine the best way to deploy the vaccine.
Progress has been slow for a number of reasons, including:
The hepatitis C virus is more variable than are the viruses that cause hepatitis A and hepatitis B. For starters, hepatitis C virus occurs in at least six genetically distinct forms (genotypes) with multiple subtypes. About 50 subtypes have been identified.
Different hepatitis C virus genotypes (variants) cause most infections in different parts of the world. A global vaccine would have to protect against all these variants of the virus.
Hepatitis C virus can infect chimpanzees, and the infection in chimpanzees is similar to that in human adults. Ethical and cost concerns, however, limit medical research with these animals.
PULSE Clinic has major campuses in Central Hong Kong, Hong Kong island; Central Kuala Lumpur (Bukit Bintang), Malaysia; Center Silom), Bangkok; and Center Sukhumvit, Bangkok, Thailand.
Malaysia
PULSE Clinic Bukit Bintang, Kuala Lumpur info.kl@pulse-clinic.com Tel: +60321102122, Whatsapp +601165388678
PULSE Clinic Bangsar, Kuala Lumpur info.kl@pulse-clinic.com Tel: +60321102122, Whatsapp +601165388678
Hong Kong
PULSE Clinic Central, Hong Kong info.hk@pulse-clinic.com Tel: +852 2389 8250
Singapore
PULSE Clinic Tanjong Pagar, Singapore info.sg@pulse-clinic.com Tel: +6569745919, +6569745908
Thailand
PULSE Clinic Silom Bangkok info.silom@pulse-clinic.com Tel: +66959156385
PULSE Clinic Nana Bangkok info.nana@pulse-clinic.com Tel: +66959156385
PULSE Clinic Patong Beach, Phuket info.phuket@pulse-clinic.com Tel: +66076633368, +66952615282
PULSE Clinic Sukhumvit 37, Bangkok (Open April 2021)
PULSE Clinic Airport Link Phayathai, Bangkok (Open April 2021)
EU Health – Executive Health center Asoke, Bangkok (Coming soon)
EU Health – Executive Health center Ploenchit, Bangkok (Coming soon)
Other Countries Without PULSE CLINICS and EU Health & Wellness, contact #PULSEcliniconline
download PULSE CLINIC mobile application here
Trust PULSE CLINIC to take care of your health like other 45000 people from over 130 countries. We provide discreet professional service with high privacy. Here to help, not to judge.